MTRR Genotype

If you have ever wondered why your homocysteine number does not match how clean your diet looks, or why a relative had a heart event despite normal cholesterol, part of the answer can sit in a single inherited letter change in your DNA. The MTRR (methionine synthase reductase) gene carries instructions for an enzyme that keeps a key folate and B12 reaction running, and common variants in this gene have been studied in connection with homocysteine, heart disease, neural tube defects, and other conditions. No major clinical guideline currently recommends routine MTRR genotyping, so the result is best used as one input among many.

This is a one-time genetic test. The result does not change. What changes is how you use it: to inform earlier monitoring of homocysteine, folate, and B12, and to support decisions before a problem shows up on a standard panel.

What MTRR Does in Your Body

MTRR (methionine synthase reductase) is a gene that codes for an enzyme. That enzyme keeps another enzyme, called methionine synthase, working properly. Together they help recycle homocysteine (an amino acid linked to blood vessel damage when it builds up) back into methionine, the building block your cells use to run methylation, the chemical tagging system that controls gene activity, DNA repair, and many other processes.

The most studied variant is called A66G (also known as rs1801394). It swaps one amino acid for another (isoleucine for methionine, sometimes written I22M) inside a part of the enzyme that interacts with its partner. A different variant deep inside the gene (in intron 1) reduces how much MTRR enzyme your cells make at all. Both can leave the homocysteine-to-methionine recycling pathway running less efficiently, especially when folate or vitamin B12 are low.

Effects on Homocysteine and Folate Status

The clearest measurable effect of MTRR variants is on homocysteine, the amino acid that builds up when this pathway slows down. In a study of 601 men, the 66AA genotype was linked to a moderate increase in plasma homocysteine, independent of folate and B12 levels. This is counterintuitive, because for other outcomes (such as congenital heart disease and neural tube defects) the G allele is often described as the risk allele. The literature is genuinely mixed on which allele raises homocysteine in which population. A separate study found that healthy people carrying two copies of the intron-1 C variant (a different MTRR variant from A66G) had significantly higher plasma homocysteine than people with the standard version.

The picture is not uniform. Other large studies in different populations, including the NHLBI Family Heart Study, found no clear effect of A66G on fasting homocysteine. This is one reason this gene is best thought of as one of several modest contributors, not a single switch. The signal often shows up most clearly when you combine MTRR with other genetic and nutritional factors.

Folate status is the main amplifier. In one study, people carrying two or more risk genotypes across MTHFR, MTR, and MTRR had nearly four times the odds of folate deficiency compared with people carrying none. A combined-variant study found that the MTHFR 677TT genotype together with the MTRR 66 A-to-G change pushed plasma homocysteine higher than either variant alone.

Heart Disease Risk

Several lines of human evidence connect MTRR variants to heart problems, with the strongest signals in congenital heart disease and, more inconsistently, in premature coronary artery disease.

A meta-analysis pooling multiple studies reported that the MTRR 66 G allele was associated with about 35% higher odds of congenital heart disease compared with the A allele (pooled odds ratio 1.35). A separate meta-analysis found the same variant was significantly linked to congenital heart disease risk in Asian populations specifically. A large study of 4,610 people from the Han Chinese population identified a different MTRR variant in intron 1 (c.56+781 A>C) that reduced MTRR expression, raised homocysteine, and was tied to roughly 1.4 times higher congenital heart disease risk in heterozygous AC carriers and about 1.84 times higher risk in CC carriers.

In adults, the 66GG genotype was linked to about 1.5 times the risk of premature coronary artery disease in one study, with the effect independent of homocysteine. However, a larger meta-analysis of 23 case-control studies concluded that MTRR A66G was not associated with coronary heart disease risk in European populations, and a French study even found the AA genotype associated with coronary artery disease. Other studies in folate-fortified populations also found no clear link. Taken together, the adult cardiovascular evidence is mixed, and this genotype should be treated as one input among many rather than a verdict.

Reconciling Mixed Findings

Two patterns can look contradictory at first: some studies show MTRR variants raise homocysteine and disease risk, while others find no effect, and the allele implicated is not always the same one. Part of the resolution is context. The variant changes how efficiently a folate and B12-dependent reaction runs. When folate and B12 are abundant (as in countries with folic acid fortification), there is enough substrate to keep the reaction going even with a less efficient enzyme. When folate or B12 are low, or when another folate-pathway variant is also present, the same MTRR change starts to matter more. Part of the picture is also that different alleles may matter for different outcomes: the AA genotype has been tied to higher homocysteine in some cohorts, while the G allele has been tied to disease outcomes likely through additional mechanisms. Your genotype is a baseline, not a fixed prediction.

Pregnancy and Birth Defects

MTRR variants have been studied extensively in mothers and pregnancies because folate and homocysteine balance is critical to early development. In a meta-analysis on neural tube defects, the maternal 66GG genotype increased the risk of spina bifida by 2.1 times, with the effect amplified when vitamin B12 was low. A Chinese study reported that mothers with two copies of the 66 A-to-G change had a 2.81-fold increased risk of having a child with Down syndrome, consistent with an earlier U.S. study (Hobbs and colleagues, 2000) that found a 2.57-fold increase.

A different MTRR variant, rs1532268 TT, was associated with about 2.8 times higher odds of neural tube defects in an Indian population. Findings are not universal: in a prospective Chinese cohort of 939 women with adequate folate intake, MTRR A66G was not linked to preterm birth, low birth weight, or small-for-gestational-age babies. As with the heart disease data, folate sufficiency softens the effect of the variant.

Cancer and Other Conditions

MTRR genotype has been associated with cervical cancer risk in one analysis, where the G allele appeared more often in cervical cancer cases than in healthy controls. Findings in other cancers are mixed and sometimes go in the opposite direction: in adults with acute lymphoblastic leukemia, certain MTRR 66AG genotypes were associated with about a 4.2-fold reduction in leukemia risk, and the 66GG genotype with a 2-fold reduction in low-grade non-Hodgkin lymphoma risk in a single study. These specific protective effects are outliers compared with broader cancer meta-analyses, which generally find only modest increases in overall cancer risk (odds ratios around 1.03 to 1.08) with the G allele, so the single-study numbers should not be treated as settled.

In type 1 diabetes, the 66GG genotype was linked to a lower rate of early kidney protein leakage, possibly because homocysteine ran slightly lower in these carriers. In a study of patients receiving high-dose methotrexate for blood cancers, the A allele of rs1801394 was significantly associated with chemotherapy-related kidney injury. These findings remain exploratory and have not been turned into routine clinical guidance.

One-Time Result, Lifetime Use

Your MTRR genotype is fixed at conception and does not change. There is no value in repeating this specific test. The ongoing tracking happens on the downstream markers your genotype influences: homocysteine, folate, and vitamin B12. A reasonable cadence is to get a baseline on those three labs, retest 3 to 6 months after any meaningful change in supplementation or diet, and then at least annually to confirm your numbers stay where you want them.

This trending is where the real signal lives. The genotype tells you whether you have a structural predisposition to homocysteine running higher when folate or B12 are limited. The repeated labs tell you whether that predisposition is actually playing out in your body right now and whether what you are doing is keeping it in check.

When Results Can Be Misleading

• Variant panel coverage: this test detects the specific variants its assay is designed to identify (usually A66G and sometimes a small number of others). A negative result does not rule out other rare MTRR variants that could still influence your enzyme function.
• Ethnic allele frequency differences: the 66G allele varies in frequency by ancestry. In Han Chinese samples, the 66G allele has been reported at roughly 25 to 29% with about 6 to 8% carrying two copies. The clinical meaning of a result depends partly on your ancestral background.
• Clinical-grade vs direct-to-consumer reports: if you have seen this variant on a 23andMe-style report, that result was generated for ancestry and wellness purposes and may not match the precision of a clinical-grade genotype call. Confirmatory testing through a clinical lab is reasonable if a decision rides on the result.
• Variants of uncertain significance: occasionally a lab reports an unexpected change in MTRR with unclear clinical meaning. These should be interpreted carefully, ideally with a genetic counselor, rather than treated as a clear risk signal.

What to Do With an At-Risk Result

A risk-associated MTRR genotype is not a diagnosis, and no major clinical guideline currently recommends routine MTRR genotyping for cardiovascular risk, pregnancy planning, or cancer screening. It is a reason to look harder at the labs that reflect whether the pathway is actually struggling. If you carry the 66G allele or another risk variant, useful next steps are to order homocysteine, serum folate, and vitamin B12, and to consider methylmalonic acid if B12 status is unclear. Knowing your MTHFR genotype matters too, since combined variants in MTHFR and MTRR have stronger effects than either alone.

If you are planning a pregnancy, this result is worth discussing with an obstetrician familiar with one-carbon metabolism, because folate status in early pregnancy matters most. If you have a personal or family history of premature heart disease, a lipidologist or preventive cardiologist can help integrate this signal with your full cardiovascular workup. A genetic counselor can help you decide whether to test biological relatives, since they may share the variant.